Research and Markets: Global Hemorrhage Pipeline Review Report, H1 2013 Edition

Fri Jun 7, 2013 12:32pm EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: Global Hemorrhage Pipeline Review Report, H1 2013 Edition

Research and Markets ( has announced the addition of the "Hemorrhage - Pipeline Review, H1 2013" report to their offering.

'Hemorrhage - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage.


- A snapshot of the global therapeutic scenario for Hemorrhage.

- A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Hemorrhage pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Involved in Hemorrhage Therapeutics Development

  • Thrombotargets Corporation
  • QRxPharma Limited

Drug Profiles

  • Q-8008
  • TT-111
  • TT-112
  • Q-8010
  • epoetin alfa
  • Resusix
  • ibuprofen
  • HDFx
  • V-0801
  • Fibrinogen Intravenous

For more information visit

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.